State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China.
AAPS PharmSciTech. 2013 Sep;14(3):1236-43. doi: 10.1208/s12249-013-0005-7. Epub 2013 Aug 10.
The aim of the study was to investigate the potential of nanosuspension to enhance the bioavailability of SKLB610 (Biopharmaceutical Classification System class II drug), a bioactive anticancer compound synthesized in our labs. SKLB610 nanosuspensions were prepared using wet media milling. Physicochemical characteristics of the nanosuspensions were evaluated, including particle size and distribution, dissolution, transmission electron microscopy, atomic force microscopy, thermogravimetric analysis, and X-ray powder diffractometry. The dissolution rate of SKLB610 was greatly improved in nanosuspensions, compared to crude SKLB610. Pharmacokinetic studies in rats demonstrated that the oral bioavailability of SKLB610 in nanosuspension (89.4%) was 2.6-fold higher than in coarse suspension (34.1%). Stabilizer type, milling time, and milling speed had a significant effect on particle size of the SKLB610 nanosuspensions. Nanosuspensions effectively improved the dissolution rate and bioavailability of the water-insoluble drug SKLB610 by reducing the compound particle size to the nanoscale and employing a proper formulation.
本研究旨在探讨纳米混悬剂提高 SKLB610(生物药剂学分类系统 II 类药物)生物利用度的潜力,SKLB610 是我们实验室合成的一种具有生物活性的抗癌化合物。采用湿磨法制备 SKLB610 纳米混悬剂。对纳米混悬剂的理化性质进行了评价,包括粒径和分布、溶出度、透射电子显微镜、原子力显微镜、热重分析和 X 射线粉末衍射。与粗品 SKLB610 相比,纳米混悬剂中 SKLB610 的溶出速率大大提高。大鼠药代动力学研究表明,纳米混悬剂中 SKLB610 的口服生物利用度(89.4%)是粗混悬剂(34.1%)的 2.6 倍。稳定剂类型、研磨时间和研磨速度对 SKLB610 纳米混悬剂的粒径有显著影响。纳米混悬剂通过将化合物粒径减小到纳米级并采用适当的配方,有效提高了难溶性药物 SKLB610 的溶出速率和生物利用度。